Parker Highlander’s pharmaceutical practice group develops comprehensive patent prosecution and portfolio management strategies for the full range of pharmaceutical inventions, including new chemical entities, stereoisomers, polymorphic forms, second medical uses, formulations, dosage regimes, and personalized medicine. Important practice considerations include maximizing patent protection after regulatory approval has been obtained (e.g., patent term extension under Hatch-Waxman, supplemental protection certificates (SPCs) in Europe) and aligning claim language with a drug’s FDA-approved label. Our group builds on a broad and diverse skill set, which includes advanced academic degrees (Ph.D.s in Chemistry, Molecular Biology and Neuroscience) and relevant industry experience (Bayer AG and Introgen Therapeutics, Inc.).
Steve Highlander and Mark Voges, “Reference Composition” not “Lead Compound”: Recent Developments in Case Law for Obviousness of Pharmaceutical Composition Claims,” Pharm. Pat. Analyst, 2012, 1(4), 385-92.